期刊
ONCOTARGET
卷 5, 期 16, 页码 6976-6982出版社
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.2106
关键词
PTPRD; CDKN2A
资金
- National Institutes of Health [F31CA171566, R01CA154767]
- Memorial Sloan Kettering Brain Tumor Center
- Molecular Cytology Core Facility grant [P30CA008748]
PTPRD encodes the protein tyrosine phosphatase receptor type D and is frequently inactivated across many human cancers. Despite its frequent inactivation, it is unknown whether loss of PTPRD promotes tumorigenesis in vivo. PTPRD is located on chromosome 9p, as is CDKN2A, and the two loci are frequently deleted together. Here, we show that co-deletion of Ptprd and Cdkn2a cooperate to accelerate tumorigenesis. Interestingly, heterozygous loss of Ptprd was sufficient to promote tumorigenesis in our model, suggesting that Ptprd may be a haploinsufficient tumor suppressor. The loss of Ptprd resulted in changes to the tumor spectrum in mice and increased the frequency of lymphomas. In total, we reveal that Ptprd is a tumor suppressor that can promote tumorigenesis in concert with Cdkn2a loss.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据